Chromocell Therapeutics (CHRO) Competitors $1.68 +0.05 (+3.07%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.72 +0.04 (+2.32%) As of 02/21/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CHRO vs. ELYM, ICCC, FBLG, NRXP, OCX, SPRO, ESLA, BRNS, KZR, and SCYXShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Eliem Therapeutics (ELYM), ImmuCell (ICCC), FibroBiologics (FBLG), NRx Pharmaceuticals (NRXP), OncoCyte (OCX), Spero Therapeutics (SPRO), Estrella Immunopharma (ESLA), Barinthus Biotherapeutics (BRNS), Kezar Life Sciences (KZR), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Eliem Therapeutics ImmuCell FibroBiologics NRx Pharmaceuticals OncoCyte Spero Therapeutics Estrella Immunopharma Barinthus Biotherapeutics Kezar Life Sciences SCYNEXIS Eliem Therapeutics (NASDAQ:ELYM) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings. Does the MarketBeat Community prefer ELYM or CHRO? Eliem Therapeutics received 8 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Chromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor ELYM or CHRO? In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Chromocell Therapeutics'average media sentiment score. Company Overall Sentiment Eliem Therapeutics Neutral Chromocell Therapeutics Neutral Which has higher valuation & earnings, ELYM or CHRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.77Chromocell TherapeuticsN/AN/A-$7.38MN/AN/A Is ELYM or CHRO more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Chromocell Therapeutics N/A N/A -453.90% Do analysts prefer ELYM or CHRO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ELYM or CHRO? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryChromocell Therapeutics beats Eliem Therapeutics on 7 of the 9 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$9.83M$3.11B$5.84B$20.31BDividend YieldN/A1.55%4.75%3.64%P/E RatioN/A27.4925.4734.71Price / SalesN/A329.47447.5815.49Price / CashN/A168.8738.0120.26Price / Book-1.023.687.644.80Net Income-$7.38M-$71.72M$3.18B$1.02B7 Day Performance-10.64%-2.50%-1.99%-1.07%1 Month Performance-37.78%-0.32%-0.42%-1.11%1 Year Performance-65.00%-12.32%16.51%13.69% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.68+3.1%N/A-64.9%$9.83MN/A0.004ELYMEliem TherapeuticsN/A$1.52-4.4%N/A-44.5%$45.22MN/A-2.879ICCCImmuCell0.1124 of 5 stars$5.05+1.0%N/A+2.4%$45.00M$17.47M-10.1070Upcoming EarningsNews CoverageFBLGFibroBiologics2.2572 of 5 stars$1.23-4.7%$13.00+956.9%-90.9%$44.78MN/A0.0010High Trading VolumeNRXPNRx Pharmaceuticals2.6644 of 5 stars$2.85-3.1%$31.67+1,011.1%-94.9%$44.75MN/A-1.332OCXOncoCyte2.4404 of 5 stars$2.56+7.6%$4.42+72.5%-13.7%$44.68M$709,000.000.00120Gap UpSPROSpero Therapeutics4.332 of 5 stars$0.82-0.2%$5.00+513.5%-45.0%$44.43M$103.78M11.64150ESLAEstrella Immunopharma2.7907 of 5 stars$1.22+8.0%N/A+42.3%$44.14MN/A-4.69N/AAnalyst ForecastNews CoverageGap UpBRNSBarinthus Biotherapeutics2.8043 of 5 stars$1.09+5.3%$5.17+374.0%-61.5%$43.85M$14.97M-0.73107KZRKezar Life Sciences2.9052 of 5 stars$5.89+0.3%$39.50+570.6%-27.4%$43.00M$7M-0.4560SCYXSCYNEXIS0.5253 of 5 stars$1.12-4.3%N/A-37.1%$42.50M$140.14M-1.5160 Related Companies and Tools Related Companies Eliem Therapeutics Competitors ImmuCell Competitors FibroBiologics Competitors NRx Pharmaceuticals Competitors OncoCyte Competitors Spero Therapeutics Competitors Estrella Immunopharma Competitors Barinthus Biotherapeutics Competitors Kezar Life Sciences Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CHRO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRO Stock Alerts